With Two Deals In Place, Amerigen Looks To Leverage China For Branded Generics
This article was originally published in PharmAsia News
Executive Summary
U.S. startup looks to tap into China’s generic market – both in China and back home in the states.
You may also be interested in...
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets
Shanghai Fosun Omni Pharma Execs On China Following A Different Pharma Model Than India: An Interview With PharmAsia News (Part 1 of 2)
Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a JV between two former principal R&D leaders from Ivax/Tevaand Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and COO Shaochuan Zeng, the two former leaders from Ivax/Teva, spoke with PharmAsia News about their operation and Chinese pharmas going international.
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.